David A. Siegel Vanda Pharmaceuticals Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 809,200 shares of VNDA stock, worth $3.49 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
809,200
Previous 235,200
244.05%
Holding current value
$3.49 Million
Previous $1.08 Million
253.94%
% of portfolio
0.01%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding VNDA
# of Institutions
152Shares Held
45.1MCall Options Held
33.3KPut Options Held
1M-
Black Rock Inc. New York, NY8.14MShares$35.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.57MShares$15.4 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.45MShares$14.9 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.12MShares$13.4 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.59MShares$11.1 Million0.0% of portfolio
About Vanda Pharmaceuticals Inc.
- Ticker VNDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,561,500
- Market Cap $244M
- Description
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...